A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma

Journal of Neuro-Oncology

Volumn 66, Issue 3, 2004, Pages 365-375

  Parker, Ricardo J ^a   Fruehauf, John P ^a,b   Mehta, Rita ^a,b   Filka, Emese ^c   Cloughesy, Timothy ^c  

^a Oncotech Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Confidence interval; CPT 11; Extreme drug resistance; Intermediate drug resistance; Low drug resistance; Malignant glioma; Percent cell growth inhibition; Progressive disease; SN38; Stable disease; Survival; Time to tumor progression

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARMUSTINE; CISPLATIN; IRINOTECAN; ISOTRETINOIN; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; ASSAY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FISHER EXACT TEST; FOLLOW UP; GLIOMA; HUMAN; IN VITRO STUDY; KAPLAN MEIER METHOD; MANTEL HAENSZEL TEST; PHASE 2 CLINICAL TRIAL; PREDICTION; PROSPECTIVE STUDY; RECURRENT CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1342329735     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000014549.77646.f6     Document Type: Article

References (34)

1. Silverberg E, Lubera JA: Cancer statistics. CA Cancer J Clin 39(1): 3-20, 254 and 399 (comments), 1989.
2. Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: The national survey of intracranial neoplasms. Neurology 35: 219-226, 1985
3. Hochberg FH, Pruitt AA: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907-911, 1980.
4. Friedman H, Cokgor I, Kerby T, Lawless A, Rich J, Stewart E, Rasheed K, Affronti M, Tourt-Uhlig S, Provenzale J, McLendon R, Colvin O, Bigner D, Malczyn J, Friedman A, Miller L: Phase I trial of CPT-11 plus BCNU in malignant glioma. Proc Am Soc Clin Oncol 18: 150a, A577, 1999
5. Colvin OM, Cokgor I, Ashley DM, Kerby T, Arbuck S, Malczyn J, Miller L, Cloughesy T, Houghton PJ, Rich J, Friedman AH, Friedman HS: Irinotecan treatment of adults with recurrent or progressive malignant glioma. Proc Am Soc Clin Oncol 17: 387a, A1493, 1998
6. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughesy T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor L, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525, 1999
7. Reid J, Buckner J, Schaaf L, Novotny P, Wright K, Kimmel D, Miller L: Pharmacokinetics of irinotecan (CPT-11) in recurrent glioma patients: Results of an NCCTG phase II trial. Proc Am Soc Clin Oncol 18: 141a, A540, 1999
8. Filka E, Nelson G, Friedman H, Kabbinavar F, Miller L, Menco H, Cloughesy T: Intrapatient dose escalation of irinotecan in patients with recurrent malignant glioma receiving anticonvulsants. Proc Am Soc Clin Oncol 18: 144a, A552, 1999
9. Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI et al.: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11(11): 2194-2204, 1993
10. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette MA, Madelaine I, Marty ME, Mathieu-Boue A: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54(16): 4347-4354, 1994
11. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst 83: 1164-1168, 1991
12. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446-449, 1994
13. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D: Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221, 1995
14. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229, 1992
15. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M et al.: An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912, 1990
16. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, Ohashi Y, Ota K: Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 study group on hematological malignancy. Br J Oncol 70(4): 771-774, 1994
17. Ptiot HC: US pivotal studies of irinotecan in colorectal carcinoma. Oncology 12(8 Suppl. 6): 48-53, 1998
18. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135, 1996
19. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15: 2910-2919, 1997
20. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-3725, 1994
21. Takimoto CH, Arbuck S: The camptothecins. In: Chabner BA and Longo DL (eds) Cancer Chemotherapy and Biotherapy. 2nd edn., Lippincott-Raven Publishers, Philadelphia, 1996, pp. 463-484
22. Hsiang YH, Liu LF: Identification of mammalian DNA topo-I as an intracellular target for the anticancer drug camptothecin. Cancer Res 48: 1722-1726, 1988
23. Voigt W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM: Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res 18: 3499-3505, 1998
24. Sun M, Duann P, Lin CT, Zhang H, Liu LF: Rapid chromatin structural alteration induced by topoisomerase I-mediated DNA damage. Ann NY Acad Sci 922: 340-342, 2000
25. Mehta RS, Cloughesy T, Parker R, Fruehauf JP: Predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma: A prospective trial. Proc Am Soc Clin Oncol 18: 219a, A843, 1999
26. Kern DM, Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82: 582-588, 1990
27. Mehta R, Bornstein R, Yu I-R, Parker RJ, McLaren CE, Nguyen KP, Li K-T, Fruehauf JP: Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 66: 225-237, 2001
28. Holloway RW, Mehta RS, Finkler NJ, Li K-T, McLaren CE, Parker RJ, Fruehauf JP: Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87: 8-16, 2002
29. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP: Levels of multidrug resistance (MDR1) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998
30. Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK: Development of miniaturized, improved nucleic acid-precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 45: 5435-5441, 1985
31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assn 53: 457-481, 1958
32. Parker RJ, Kyshtoobayeva A, Mehta R, Brem H, Brem S, Vanier V, Barger G, Fruehauf JP: In vitro drug response and prognostic marker profiles in primary brain tumors. Proc Am Assn Cancer Res 41: 257, A1637, 2000
33. Kaneda N, Nagata H, Furuta T, Yokokura T: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720, 1990
34. Fruehauf JP, Bosanquet AG: In vitro determination of drug response: A discussion of clinical applications. PPO Update 7: 1-17, 1993